German giant Bayer (ETR: BAYN) has released its Q4 2024 financial results, reporting a 0.7% year-on-year (YOY) growth in constant currency terms, with global group sales for the twelve months reaching EUR 46.6 billion (USD 50.3 billion).
Sales Performance by Division
Crop Sciences sales declined by 2% to EUR 22.2 billion (USD 24 billion). Pharmaceuticals sales increased by 3.3% to EUR 18.1 billion (USD 19.6 billion), while Consumer Healthcare sales rose by 1.9% to EUR 5.9 billion (USD 6.3 billion).
Pharmaceuticals Segment Highlights
Drug sales within the Pharmaceuticals segment amounted to EUR 15.4 billion (USD 16.6 billion), representing a 4.5% YOY increase. Newly launched drugs experienced significant sales growth, primarily driven by Nubeqa (darolutamide) and Kerendia (finerenone), which saw increases of 78.2% and 73.9%, respectively. Eylea (aflibercept), an ophthalmic drug, sustained its growth momentum with a 5.1% YOY increase. The Radiology business, encompassing CT Fluid Delivery, Ultravist, and Gadovist, reported a double-digit percentage sales increase. Sales of Adempas (riociguat), a pulmonary arterial hypertension (PAH) therapy, surged by 10.5% YOY, with notably strong growth in the US. Conversely, Xarelto (rivaroxaban) faced generic competition, leading to a continuous sales decline of 13% YOY.
Financial Strategy
The Pharmaceuticals segment reduced expenses for late-stage clinical development projects and lowered sales costs for mature products. Meanwhile, it increased investment in early-stage research and development, cell and gene therapy, and chemical proteomics technology.
2025 Sales Outlook
Bayer anticipates generating global sales in the range of EUR 45 billion to EUR 47 billion in 2025.-Fineline Info & Tech
Leave a Reply